Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Valinotti

Physician Assistant Bay Shore, NY Physician Assistant

NPI 1568018588 CMS profile 6238503

332 E Main St Ste 1, Bay Shore, NY 11706

Open in the dashboard

General payments

$7,731

370 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Valinotti of Bay Shore, NY is reported in the CMS Open Payments database as having received $7,731 across 370 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,325 113
2024 General $1,923 90
2023 General $1,769 85
2022 General $1,539 75
2021 General $175 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Valinotti
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mary Valinotti were reported at $2,325. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mary Valinotti Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $175 $132 $37–$438 $132
2022 $1,539 $155 $48–$522 $149
2023 $1,769 $167 $52–$557 $160
2024 $1,923 $178 $55–$600 $164
2025 $2,325 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sun Pharmaceutical Industries Inc. $970 51 payments
  2. Incyte Corporation $833 40 payments
  3. Arcutis Biotherapeutics, Inc. $589 20 payments
  4. Dermavant Sciences, Inc. $578 53 payments
  5. Lilly USA, LLC $563 20 payments
  6. AbbVie, Inc. $556 29 payments
  7. Regeneron Healthcare Solutions, Inc. $475 14 payments
  8. Genzyme Corporation $461 22 payments
  9. Janssen Biotech, Inc. $415 18 payments
  10. Journey Medical Corporation $277 6 payments
  11. Other $2,015 97 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,344 366 payments
  2. Education $387 4 payments
Products named General payments · program years 2021–2025
  1. Winlevi $883 46 payments
  2. OPZELURA $833 40 payments
  3. DUPIXENT Immunology $749 32 payments
  4. VTAMA $587 54 payments
  5. Zoryve $540 18 payments
  6. Absorica LD $495 24 payments
  7. DUPIXENT Inflammation And Immunology $406 12 payments
  8. TREMFYA $361 15 payments
  9. TALTZ $272 16 payments
  10. Otezla $266 11 payments
  11. Other $3,164 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

453

Median for Physician Assistant: 241

Drug cost

$9,193

Median for Physician Assistant: $4,110

Branded share of claims

5.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 68 $3,022
Betamethasone Dipropionate Generic 36 $1,875
Triamcinolone Acetonide Generic 106 $1,515
Ketoconazole Generic 71 $1,405
Mupirocin Generic 69 $519
Cephalexin Generic 16 $346
Valacyclovir Valacyclovir Hcl Brand 25 $219
Hydrocortisone Generic 43 $185
Prednisone Generic 19 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $370
$370 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $250
$250 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $135
  • GENZYME CORPORATION $65
$199 — —
OPZELURA
  • Incyte Corporation $179
$179 — —
TREMFYA
  • Janssen Biotech, Inc. $175
$175 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record